Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Human immunodeficiency virus type 1 (HIV-1) integrase–viral DNA intasome is a specialized nucleoprotein complex that plays a critical role in the viral life cycle by facilitating the integration of viral genetic material into the host cell genome (Passos et al., 2017, Science). This complex is composed of a multimeric assembly of the viral integrase (IN) enzyme—typically a tetramer or higher-order oligomer—bound to the ends of the blunt-ended viral DNA (vDNA) produced during reverse transcription (Engelman & Cherepanov, 2012, Nature Reviews Microbiology). The intasome's primary function is to catalyze the strand transfer reaction, where it inserts the viral DNA into the host's chromosomal DNA, a step that is essential for establishing a productive and permanent infection (Craigie & Bushman, 2012, Cold Spring Harbor Perspectives in Medicine). Because integration is a unique and vital step for HIV-1, the intasome serves as the primary pharmacological target for Integrase Strand Transfer Inhibitors (INSTIs), which are a cornerstone of modern antiretroviral therapy (Hare et al., 2010, Nature). These drugs, including dolutegravir and bictegravir, bind specifically to the metal-ion-containing active site of the intasome, effectively blocking the attachment of host DNA and halting viral replication (Anstett et al., 2017, Current Opinion in HIV and AIDS).
Integrase strand transfer inhibition (INSTI), which prevents the covalent insertion of viral DNA into the host cell genome by binding to the intasome active site.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human immunodeficiency virus type 1 integrase–viral DNA intasome (HIV-1 IN intasome) (HIV-1 IN intasome).